Fetal and Neonatal Alloimmune Thrombocytopenia: Harvesting the Evidence to Develop a Clinical Approach to Management

ABSTRACT

Neonatal alloimmune thrombocytopenia (NAIT) is the most common cause of severe thrombocytopenia in an otherwise healthy newborn. The most serious complication is intracranial hemorrhage, which can occur either in the fetus or the newborn. Despite the known serious sequelae, both antenatal management and neonatal treatment modalities are plagued by the lack of gold standard evidence to appropriately direct therapy. Maternal, risk-based therapeutic approaches range from invasive protocols to relatively benign noninvasive strategies to avoid serious procedural complications. Intravenous immunoglobulin (IVIG) with or without steroids and fetal blood sampling constitute the mainstay of antenatal management. Neonatal interventions principally focus on the use of antigen-negative compatible or random donor platelets and IVIG. While awaiting the results of controlled trials, each institution must develop a standardized, collaborative, multidisciplinary approach to the screening, diagnostic evaluation, and management of unexpected and anticipated NAIT based on experience, product availability, and emerging scientific data.

KEYWORDS

Maternal - fetal - neonatal - alloimmune thrombocytopenia - management

REFERENCES

• 1 Burrows R F, Kelton J G. Fetal thrombocytopenia and its relation to maternal thrombocytopenia.  N Engl J Med. 1993;  329 1463-1466
• 2 Metcalfe P, Watkins N A, Ouwehand W H et al.. Nomenclature of human platelet antigens.  Vox Sang. 2003;  85 240-245
• 3 Gruel Y, Boizard B, Daffos F, Forestier F, Caen J, Wautier J L. Determination of platelet antigens and glycoproteins in the human fetus.  Blood. 1986;  68 488-492
• 4 Blanchette V S, Chen L, de Friedberg Z S, Hogan V A, Trudel E, Décary F. Alloimmunization to the PlA1 platelet antigen: results of a prospective study.  Br J Haematol. 1990;  74 209-215
• 5 Doughty H A, Murphy M F, Metcalfe P, Waters A H. Antenatal screening for fetal alloimmune thrombocytopenia: the results of a pilot study.  Br J Haematol. 1995;  90 321-325
• 6 Durand-Zaleski I, Schlegel N, Blum-Boisgard C, Uzan S, Dreyfus M, Kaplan C. Immune Thrombocytopenia Working Group . Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs.  Am J Perinatol. 1996;  13 423-431
• 7 Kjeldsen-Kragh J, Killie M K, Tomter G et al.. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia.  Blood. 2007;  110 833-839
• 8 Turner M L, Bessos H, Fagge T et al.. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a.  Transfusion. 2005;  45 1945-1956
• 9 Williamson L M, Hackett G, Rennie J et al.. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening.  Blood. 1998;  92 2280-2287
• 10 Blanchette V S, Johnson J, Rand M. The management of alloimmune neonatal thrombocytopenia.  Baillieres Best Pract Res Clin Haematol. 2000;  13 365-390
• 11 Rayment R, Brunskill S J, Stanworth S, Soothill P W, Roberts D J, Murphy M F. Antenatal interventions for fetomaternal alloimmune thrombocytopenia.  Cochrane Database Syst Rev. 2005;  (1 Issue 1) CD004226
• 12 Mueller-Eckhardt C, Mueller-Eckhardt G, Willen-Ohff H et al.. Immunogenicity of and immune response to the human platelet antigen Zwa is strongly associated with HLA-B8 and DR3.  Tissue Antigens. 1985;  26 71-76
• 13 Davoren A, McParland P, Crowley J, Barnes A, Kelly G, Murphy W G. Antenatal screening for human platelet antigen-1a: results of a prospective study at a large maternity hospital in Ireland.  BJOG. 2003;  110 492-496
• 14 Maslanka K, Guz K, Zupanska B. Antenatal screening of unselected pregnant women for HPA-1a antigen, antibody and alloimmune thrombocytopenia.  Vox Sang. 2003;  85 326-327
• 15 Dreyfus M, Kaplan C, Verdy E, Schlegel N, Durand-Zaleski I, Tchernia G. Immune Thrombocytopenia Working Group . Frequency of immune thrombocytopenia in newborns: a prospective study.  Blood. 1997;  89 4402-4406
• 16 de Moerloose P, Boehlen F, Extermann P, Hohfeld P. Neonatal thrombocytopenia: incidence and characterization of maternal antiplatelet antibodies by MAIPA assay.  Br J Haematol. 1998;  100 735-740
• 17 Uhrynowska M, Niznikowska-Marks M, Zupańska B. Neonatal and maternal thrombocytopenia: incidence and immune background.  Eur J Haematol. 2000;  64 42-46
• 18 Ghevaert C, Campbell K, Walton J et al.. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia.  Transfusion. 2007;  47 901-910
• 19 Bussel J B, Zabusky M R, Berkowitz R L, McFarland J G. Fetal alloimmune thrombocytopenia.  N Engl J Med. 1997;  337 22-26
• 20 Spencer J A, Burrows R F. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis.  Aust N Z J Obstet Gynaecol. 2001;  41 45-55
• 21 Killie M K, Husebekk A, Kjeldsen-Kragh J, Skogen B. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn.  Haematologica. 2008;  93 870-877
• 22 Skogen B, Husebekk A, Killie M K, Kjeldsen-Kragh J. Neonatal alloimmune thrombocytopenia is not what it was: a lesson learned from a large prospective screening and intervention program.  Scand J Immunol. 2009;  70 531-534
• 23 Radder C M, Brand A, Kanhai H HH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it?.  Vox Sang. 2003;  84 318-325
• 24 Kanhai H HH, Porcelijn L, Engelfriet C P et al.. Management of alloimmune thrombocytopenia.  Vox Sang. 2007;  93 370-385
• 25 Kjeldsen-Kragh J, Husebekk A, Killie M K, Skogen B. Is it time to include screening for neonatal alloimmune thrombocytopenia in the general antenatal health care programme?.  Transfus Apher Sci. 2008;  38 183-188
• 26 Fretheim A. Cost-effectiveness analysis of screening for neonatal alloimmune thrombocytopenia was based on invalid assumption.  BJOG. 2008;  115 412-413 author reply 413-414, discussion 414
• 27 Killie M K, Kjeldsen-Kragh J, Husebekk A, Skogen B, Olsen J A, Kristiansen I S. Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia.  BJOG. 2007;  114 588-595
• 28 Kiefel V, Santoso S, Weisheit M, Müeller-Eckhardt C. Monoclonal antibody—specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies.  Blood. 1987;  70 1722-1726
• 29 Arnold D M, Smith J W, Kelton J G. Diagnosis and management of neonatal alloimmune thrombocytopenia.  Transfus Med Rev. 2008;  22 255-267
• 30 Kaplan C, Daffos F, Forestier F et al.. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets.  Blood. 1988;  72 340-343
• 31 Overton T G, Duncan K R, Jolly M, Letsky E, Fisk N M. Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and perinatal outcome.  Am J Obstet Gynecol. 2002;  186 826-831
• 32 Daffos F, Forestier F, Muller J Y et al.. Prenatal treatment of alloimmune thrombocytopenia.  Lancet. 1984;  2 632
• 33 Nicolini U, Rodeck C H, Kochenour N K et al.. In-utero platelet transfusion for alloimmune thrombocytopenia.  Lancet. 1988;  2 506
• 34 Birchall J E, Murphy M F, Kaplan C, Kroll H. European Fetomaternal Alloimmune Thrombocytopenia Study Group . European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia.  Br J Haematol. 2003;  122 275-288
• 35 van den Akker E S, Oepkes D, Lopriore E, Brand A, Kanhai H H. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective.  BJOG. 2007;  114 469-473
• 36 Paidas M J, Berkowitz R L, Lynch L et al.. Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis.  Am J Obstet Gynecol. 1995;  172 (2 Pt 1) 475-479
• 37 Simon H U, Späth P J. IVIG—mechanisms of action.  Allergy. 2003;  58 543-552
• 38 Koleba T, Ensom M HH. Pharmacokinetics of intravenous immunoglobulin: a systematic review.  Pharmacotherapy. 2006;  26 813-827
• 39 Bussel J B, Berkowitz R L, Lynch L et al.. Antenatal management of alloimmune thrombocytopenia with intravenous γ-globulin: a randomized trial of the addition of low-dose steroid to intravenous γ-globulin.  Am J Obstet Gynecol. 1996;  174 1414-1423
• 40 Berkowitz R L, Kolb E A, McFarland J G et al.. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia.  Obstet Gynecol. 2006;  107 91-96
• 41 Berkowitz R L, Lesser M L, McFarland J G et al.. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial.  Obstet Gynecol. 2007;  110 (2 Pt 1) 249-255
• 42 van den Akker E, Oepkes D, Brand A, Kanhai H H. Vaginal delivery for fetuses at risk of alloimmune thrombocytopenia?.  BJOG. 2006;  113 781-783
• 43 Bassler D, Greinacher A, Okascharoen C et al.. A systematic review and survey of the management of unexpected neonatal alloimmune thrombocytopenia.  Transfusion. 2008;  48 92-98
• 44 Ouwehand W H, Smith G, Ranasinghe E. Management of severe alloimmune thrombocytopenia in the newborn.  Arch Dis Child Fetal Neonatal Ed. 2000;  82 F173-F175
• 45 Bussel J B, Primiani A. Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates.  Blood Rev. 2008;  22 33-52
• 46 Mueller-Eckhardt C, Kiefel V, Grubert A et al.. 348 cases of suspected neonatal alloimmune thrombocytopenia.  Lancet. 1989;  1 363-366
• 47 Kiefel V, Bassler D, Kroll H et al.. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT).  Blood. 2006;  107 3761-3763
• 48 Win N. Provision of random-donor platelets (HPA-1a positive) in neonatal alloimmune thrombocytopenia due to anti HPA-1a alloantibodies.  Vox Sang. 1996;  71 130-131
• 49 Allen D, Verjee S, Rees S, Murphy M F, Roberts D J. Platelet transfusion in neonatal alloimmune thrombocytopenia.  Blood. 2007;  109 388-389
• 50 Bakchoul T, Sachs U J, Wittekindt B, Sclösser R, Bein G, Santoso S. Treatment of fetomaternal neonatal alloimmune thrombocytopenia with random platelets.  Pediatr Blood Cancer. 2008;  50 1293-1294
• 51 Derycke M, Dreyfus M, Ropert J C, Tchernia G. Intravenous immunoglobulin for neonatal isoimmune thrombocytopenia.  Arch Dis Child. 1985;  60 667-669
• 52 Sidiropoulos D, Straume B. The treatment of neonatal isoimmune thrombocytopenia with intravenous immunoglobin (IgG i.v.)  Blut. 1984;  48 383-386
• 53 Suarez C R, Anderson C. High-dose intravenous gammaglobulin (IVG) in neonatal immune thrombocytopenia.  Am J Hematol. 1987;  26 247-253
• 54 Ballin A, Andrew M, Ling E, Perlman M, Blanchette V. High-dose intravenous gammaglobulin therapy for neonatal autoimmune thrombocytopenia.  J Pediatr. 1988;  112 789-792
• 55 Linder N, Shapiro S C, Moser A M, Roitman J, Engelhard D. Treatment of neonatal immune thrombocytopenia with high dose intravenous γ-globulin.  Dev Pharmacol Ther. 1990;  14 205-208